Medicine & Health

WashU Medicine researchers Randall J. Bateman, MD, and David M. Holtzman, MD, were honored for their work developing diagnostic blood tests for Alzheimer’s disease with the Bayh-Dole Coalition’s 2026 American Innovator Award.

A tool developed by WashU Medicine researchers can accurately distinguish among several major neurodegenerative diseases — including Alzheimer’s, Parkinson’s, frontotemporal dementia and dementia with Lewy bodies — as well as detect when these conditions overlap, potentially improving early diagnosis, monitoring and treatment.

A study led by WashU Medicine researchers reveals molecular insights into Alzheimer’s disease, Parkinson’s disease and other dementias that could lead to earlier, more precise diagnoses.

Researchers at WashU have won $2.7 million from the National Institutes of Health (NIH) for a five-year investigation into the power of sleep to prevent, delay and diminish Alzheimer’s and other neurodegenerative diseases.

Researchers at WashU Medicine will investigate genetic and molecular factors behind the disease’s disproportionate prevalence in Caribbean populations, with the aim of identifying new drug targets.

WashU Medicine researchers engineered a new cellular immunotherapy that turns brain cells called astrocytes into super cleaners, efficiently removing amyloid beta plaques from the brains of mice.

Researchers at Washington University in St. Louis have a federal grant to further develop a fiber-based, deep-brain interface to study the relationship between neurovascular dysfunction and memory loss in Alzheimer’s disease.

WashU Medicine researchers have developed a method to predict when someone is likely to develop symptoms of Alzheimer’s disease using a single blood test.

Researchers at WashU Medicine and Weizmann Institute of Science designed a CAR-T cell therapy that reduced amyloid beta plaques in the brains of mice, pointing to a promising new approach for Alzheimer’s disease.

Ganesh Chand, an assistant professor at WashU Medicine Mallinckrodt Institute of Radiology, will study why some Alzheimer’s patients experience neuropsychiatric symptoms such as apathy and depression.